Kisspeptin 112-121

Phase 2

Kisspeptin 112-121 is one of 35 therapeutic programs targeting Hypogonadotropic Hypogonadism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hypogonadotropic HypogonadismRecruiting

AmenorrheaRecruiting

Reproductive DisorderRecruiting

Hypogonadotropic HypogonadismPhase 2

Recruiting

AmenorrheaPhase 2

Recruiting

Reproductive DisorderPhase 1

Recruiting

Competition

Competitive Landscape

30 competitors in Hypogonadotropic Hypogonadism

#DrugCompanyPhaseTrials

Femara

Andriol

3 3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Delatestryl

Human Chorionic Gonadotropin

Merck & Co.

Phase 3

5 6

Recombinant Human Chorionic Gonadotropin

Merck & Co.

Approved

1 7

Human Menopausal Gonadotropin

EMD Serono

Approved

2 8

Hcg

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

2 9

Androgel

RRepros Therapeutics Inc.

Phase 3

2 10

Luveris

Merck & Co.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Hypogonadotropic Hypogonadism

NCT05896293

Q2 2030

Phase 2Recruiting

Amenorrhea

NCT07224438

Phase 1Recruiting

Reproductive Disorder

NCT07224490

Clinical

Trials by Indication[1]

Hypogonadotropic Hypogonadism1 trial

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Recruiting·SStephanie B. Seminara, MD·Phase 2·NCT05896293·36 enrolled

Amenorrhea1 trial

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

Recruiting·SStephanie B. Seminara, MD·Phase 2·NCT07224438·20 enrolled

Reproductive Disorder1 trial

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Recruiting·SStephanie B. Seminara, MD·Phase 1·NCT07224490·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Kisspeptin 112-121. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Kisspeptin 112-121. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Stephanie B. Seminara, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SStephanie B. Seminara, MD

Kisspeptin 112-121

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2030

Trials by Indication[1]

Hypogonadotropic Hypogonadism1 trial

Amenorrhea1 trial

Reproductive Disorder1 trial

References

Drug Info

Quick Facts

Related News